Research Bridge is a venture development platform dedicated to transforming breakthrough academic research into scalable commercial ventures. Through a structured discovery and evaluation process, we identify high-potential innovations emerging from universities and research institutes worldwide. Our team works alongside researchers to develop commercial strategies, build venture structures, and connect projects with strategic investors capable of accelerating their path to market.
join the success
OUR SECTORS
Artificial intelligence is changing how every industry operates—from healthcare and biotech to manufacturing, energy and education.
Research Bridge helps researchers, universities and investors identify where AI can unlock the greatest value, strengthen research outcomes and accelerate the path to commercialisation.
Whether your project is focused on AI itself or could benefit from AI-enabled applications, we help uncover the most promising opportunities.
PhD researchers lack resources, networks, and business expertise to commercialise their innovations. Valuable research often remains confined to academic journals.
Identifying commercially viable academic research is time-consuming, fragmented across global institutions, and involves complex IP negotiations.
Technology transfer offices are under-resourced and struggle to market early-stage research effectively.
Global scouting network to identify promising PhD projects across 50+ disciplines
Proprietary evaluation algorithm assessing commercial potential, technical feasibility, and market readiness
Initial screening by domain-expert advisory board
Negotiate exclusive option agreements with universities/researchers
Establish clear IP frameworks and commercialisation rights
Prepare standardised investment packages
Curated presentation to qualified investor network
Structured investment vehicles for research funding
Ongoing management of investor-researcher relationships
Founder & CEO
With over 33 years in clinical cardiology, Dr. Maltz bridges patient care, research, and commercialisation. As the founder and managing director of a leading Harley Street clinic, he has successfully sourced, integrated, and scaled new medical technologies into his practice, turning clinical insight into profitable, patient-impacting businesses. His expertise ensures our projects are sound, and viable. He understands precisely how to translate breakthrough science into real-world adoption and revenue.
CO-FOUNDER AND CHIEF OPERATING OFFICER
Dr Amit Kaura is Chief Research Officer at Research Bridge, and Clinical Academic in Cardiology at Imperial College London and Imperial College Healthcare NHS Trust.
He specialises in translating cutting-edge research into real-world impact, with particular expertise in artificial intelligence, big data analytics, digital health and cardiovascular medicine.
Dr Kaura has led and contributed to research programmes worth more than £3 million, including projects supported by the British Heart Foundation, NIHR, Innovate UK and Imperial College London. His work focuses on using electronic health records, machine learning and digital technologies to improve diagnosis, patient care and health outcomes.
Academic Insight & Research Liaison
A recent graduate in biomedical chemistry, Aoki
bridges the gap between the lab bench and the boardroom. As a recent graduate at the forefront of biomedical chemistry, she has worked firsthand on groundbreaking projects, from designing novel drugs to engineering targeted therapeutics. Her first-hand understanding of the modern research frontier allow her to spot young, high-potential technology before it enters the mainstream, ensuring we identify tomorrow’s breakthroughs at their very genesis.
CHIEF FINANCIAL OFFICER
Mr. Maltz is Head of Real Estate and Infrastructure Investor Relations at UBS Asset Management. UBS AM is a leading real assets investment manager with US$112bn in AuM across the risk / return spectrum covering real estate, infrastructure equity and debt, as well as niche strategies. Mr. Maltz oversees the UBS Infrastructure Debt Platform (IDP) including having established a joint partnership with Swiss Life Asset Managers. He is a voting member of the Investment Committee of the IDP funds. Prior to that, Mr. Maltz was head of international distribution for BTG Pactual Private Capital Group, an asset management business investing in infrastructure, private equity and venture capital, with $6BN in AUM. Mr. Maltz was also previously head of investor relations and fundraising at KLI (BTG Pactual Commodities spin-off). Mr. Maltz has experience in launching new funds, with expertise in capital formation, strategy and operations across a fund’s lifecycle
Chief Strategy Officer
Pending bio.
Research Bridge is an innovation platform dedicated to unlocking the commercial potential of academic research. By identifying breakthrough discoveries emerging from universities and research institutes worldwide, we transform promising ideas into scalable ventures. Through rigorous evaluation, venture development support, and strategic investor connections, we enable researchers to translate scientific insight into technologies that shape the future.